Technische Daten
Status:In Vitro Diagnostic Use (IVD)
Ig Unterklasse:IgG
Immunogen:Synthetic peptide of human CD99
Vorbehandlung:ProTaqs® Antigen Enhancer I (Cat. No. 401602092)
Zelluläre Lokalisation:Membranous
Kontrolle:Ependyma, Ewing sarcoma, pancreas
Change(s) made:Complete revision
Synonyme:T-cell surface glycoprotein E, T cell surface glycoprotein E2 precursor, 12E7, Antigen identified by monoclonal 12E7 Y homolog, Antigen identified by monoclonal antibodies 12E7 F21 and O13, CD 99, CD99 antigen, CD99 molecule, CD99X, E2 antigen, Ewing Sarcoma, MIC 2, MIC 2X, MIC 2Y, MIC2, MIC2X, MIC2Y, Monoclonal antibody 12E7, MSK5X, Protein MIC2, Surface antigen MIC2.
Verfügbar in folgenden Ländern:worldwide

CD99 is an O-glycosylated transmembrane protein and the gene product of MIC2. It is expressed on EwingÍs sarcoma/primitive neuroectodermal tumor (ES/PNET) cells, Sertorli cells, pancreatic islet cells, thymocytes and other hematopoietic cells. CD99 plays a role in the T-cell adhesion, differentiation of primitive neuroectodermal cells and leukocyte migration.


[1] Gelin C, Aubrit F, Phalipon A et al. (1989) The E2 antigen, a 32 kd glycoprotein involved in T-cell adhesion processes, is the MIC2 gene product. EMBO J. 8(11): 3253Ð3259.
[2] Fellinger EJ, Garin-Chesa P, Triche TJ A et al. (1991) Immunohistochemical analysis of Ewing's sarcoma cell surface antigen p30/32MIC2. Am J Pathol. 139(2): 317Ð325.
[3] Lee EJ, Lee HG, Park SH et al. (2003) CD99 type II is a determining factor for the differentiation of primitive neuroectodermal cells. Exp Mol Med. 35(5):438-47.

Kunden, die sich für diesen Artikel interessierten, interessierten sich auch für: